Dentatorubral-pallidoluysian atrophy (DRPLA) is a dominant-inherited neurodegenerative disease characterized by selective cell loss in particular neuronal pathways. This is caused by expansion of CAG repeats in the coding region of the DRPLA gene, and the extended polyglutamine tract (polyQ) confers a toxic activity. It is valuable to characterize disease gene products for elucidation of the mechanism underlying neuron death at specific anatomical areas of the brain. Here, we define the DRPLA protein as a phosphoprotein, and c-Jun NH 2 -terminal kinase (JNK) is one of the major factors involved in its phosphorylation. Endogenous DRPLA protein was serine-phosphorylated. Phosphorylation was demonstrated in a recombinant JNK activation system in vitro and also in overexpressing cells by transfection after the JNK activation with osmotic pressure. One of the phospho-acceptor sites for JNK appearing in the DRPLA sequence was indeed phosphorylated, which was confirmed by a specific antibody raised against the phosphopeptide. Kinetic studies in the JNK recombinant system showed that expanded polyQ slightly reduced the affinity of JNK to the protein. Thus, the abnormal DRPLA protein seems to be slowly phosphorylated in a certain condition of JNK activation in patients. It may delay a process that is essential in keeping neurons alive.
INTRODUCTION
Dentatorubral-pallidoluysian atrophy (DRPLA) is a dominantly inherited neurodegenerative disease characterized by selective neuron loss in the cerebellar and pallidal outflow pathways (1) . The disease is caused by expansion of CAG repeats in the coding region of the DRPLA gene, and the extended polyglutamine tract ( polyQ) confers a toxic activity to a subset of neurons (2) (3) (4) . Several other neurodegenerative diseases including Huntington disease are also known to be caused by expansion of CAG repeats in the coding region of the respective genes (5) . Thus, these diseases are collectively called polyglutamine diseases. It has been demonstrated that over expression of extended polyQ induces apoptosis in a variety of cells (6, 7) , but the precise mechanism leading to apoptosis has not yet been settled. Previous studies have implied impairment of transcription, retardation in cleaning of misfolding proteins, sequestering of essential factors or formation of pores with extended polyQ (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Although several studies have excluded the involvement of aggregates visible under a microscope in these processes (21) (22) (23) , all the proposed mechanisms seem to imply the cohesive force of polyQ.
We have been studying the normal functions of the DRPLA product (24) (25) (26) (27) , also known as 'atrophin-1'. As a specific subset of neurons are degenerated in different polyglutamine diseases, polyQ alone is not enough to elucidate the pathogenesis of patients. We previously reported binding partners with DRPLA protein (25) . Among them, IRSp53 and DVL1 potentially activate signaling cascades of c-Jun NH 2 -terminal kinase (JNK), a family member of mitogen activated protein kinases (MAPKs), which phosphorylates serine/threonine (S/T) residues followed by proline (S/TP) (28) (29) (30) (31) (32) (33) (34) . Seven other binding partners use phosphorylated S/T as a target (25, 35) . As there are many S/TP sequences in the DRPLA protein (4) (Fig. 1) , we are interested on the phosphorylation state of the product. Recently, a DRPLA-like protein in Drosophila, Atro (or Grunge), was reported to have multiple functions in transcriptional regulation (36, 37) . It functions as a transcriptional co-repressor in the earliest stage of embryogenesis, and further participates in body patterning in multiple developmental stages as transcriptional regulators. Expression of the abnormal DRPLA protein with extended polyQ in Drosophila embryos causes deregulation of transcription. Atro/Grunge has evolved into two descendants, DRPLA and RERE, in mammals (4, 26) . Although human DRPLA protein lacks a putative DNAbinding domain in the N-terminal portion of the Drosophila homolog, it may be still be involved in transcriptional regulation as it gains additional motifs in the flanking region of polyQ. In light of these observations, we have characterized the phosphorylated state of the DRPLA protein and detected phosphorylation by JNK.
RESULTS

Endogenous DRPLA protein was phosphorylated
We first examined a phosphorylated state of the DRPLA protein in cultured cells (Fig. 2) . The major form of the DRPLA protein in human neuroblastoma cells moved to the position of a 160 kDa protein through SDS-PAGE and was visualized with anti-human DRPLA antibody (anti-DRa), as shown previously (24) . When the cell lysate was treated with alkaline phosphatase, the major form moved faster through SDS-PAGE and migrated to the same position as the in vitro translated product without post-translational modification ( Fig. 2A) . The major form precipitated with the anti-DRa antibody from the cell lysate was immuno-reactive to an antiphosphoserine antibody (anti-pS), and it almost lost the reactivity when treated with the alkaline phosphatase ( Fig. 2B and C). These results indicated that the major form of DRPLA protein in cultured cells was serine-phosphorylated.
DRPLA protein was phosphorylated by JNK in vitro
In an attempt to establish a biochemical basis for the phosphorylation, we adopted an in vitro activation system for JNK in which purified forms of recombinant protein kinases were mixed together. In this mixture, JNK3 is synergistically activated by two forms of MAPK kinase (MKK), constitutive active MKK7 and native MKK4 that is activated by constitutive active MEK kinase 1 (MEKK1), as described previously (38) (39) (40) .
In vitro translation products of DRPLA with normal or expanded repeats were subjected to the activation system and analyzed by SDS-PAGE. When incubated in the JNK mixture, the translation products migrated more slowly than the untreated counterparts (Fig. 3A, upper panel) . As the mobility shift was not observed by omission of any member of the four kinases from the reaction, the shift must be due to synergistically activated JNK as previously demonstrated. The products translated in unlabeled conditions, were radiolabeled after incubation in the mixture containing [g-32 P]ATP (Fig. 3A, lower panel) . When JNK-reacted products were further treated with alkaline phosphatase, the products moved faster than the untreated counterparts (Fig. 3B) . Thus, we concluded that the normal and abnormal forms of the DRPLA protein were phosphorylated by JNK in vitro.
A time course study of phosphorylation showed that both the normal and abnormal DRPLA proteins were fully phosphorylated within 120 min ( Fig. 3C and D) . However, a kinetic analysis showed that the affinity of JNK for the abnormal protein was lower than that of the normal protein (K m ¼ 0.59 U/ml for the normal protein and 1.11 U/ml for the abnormal protein in Fig. 3E ). Thus, the expanded polyQ reduced the affinity of JNK for the DRPLA protein.
To further investigate the phospho-acceptor sites, we produced seven non-overlapping fragments of the DRPLA protein (DR-a-i, shown in Fig. 1A ). When subjected to the recombinant system, one of the fragments, DR-f, was strongly phosphorylated in the mixture (Fig. 4) . In the absence of recombinant JNK3, the phosphorylation was completely eliminated (lanes f and f * in Fig. 4 ; note that the band for JNK3 also disappeared in lane f *). This clearly showed that the DR-f fragment was directly phosphorylated by JNK3. When the fragment was separated into two portions (DR-h and -i in Fig. 1A ), both were phosphorylated (Fig. 4 , lanes h and i). Thus, DR-f was thought to contain at least two phosphoacceptor sites, one of which was located in DR-h and the other in DR-i. Although the details were not examined, two other fragments, DR-a and -g, seem to have additional minor phospho-acceptor sites (Fig. 4 , lanes a and g).
DRPLA protein over-expressed in cells was phosphorylated by JNK
Endogenous DRPLA protein was phosphorylated as shown in Figure 2 . Then, we tested the phosphorylated state of over expressed forms of the normal and abnormal protein, tagged with HA at the N-terminal end, in neuroblastoma cells (Fig. 5 ). We chose a high osmotic pressure by adding sorbitol to the cultured medium for transient activation of JNK. As demonstrated in Figure 5A , active JNK was increased to be detectable by western blotting with an anti-active JNK antibody. Along with the stimulation, amounts of the overexpressed forms of the DRPLA protein decreased afterward. It seemed that the N-terminal portion was cleaved off in the process, although the smaller fragments were not detected with the anti-HA antibody.
We examined the mobility shift of the normal DRPLA protein expressed in cells after osmotic stress. The mobility shift of the normal DRPLA was clear after 30 min of the stimulation (Fig. 5B) , although the extent of the mobility shift shown here was less than that shown in the recombinant system (Q19 in Fig. 3A) . The mobility shift of the abnormal protein was imperceptible. After the treatment of cell lysates with alkaline phosphatase, the normal protein with the osmotic stress migrated to the basal position without stress (Fig. 5C) . Thus, the mobility shift was due to the phosphorylation state. When the cells were treated with a selective inhibitor of JNK, SP600125 (41) in the osmotic stress condition, the JNK kinase activity was inhibited as expected, and the normal protein migrated to the same position as the cells without osmotic stress (Fig. 5D) . These results showed that DRPLA protein overexpressed in cultured cells was phosphorylated by JNK.
Serine 734 of the DRPLA protein is a phospho-acceptor site by JNK
We focused on phosphorylation of serine 734 (S734) in the DR-i fragment of DRPLA protein (double-underlined in Fig. 1B) , because the flanking sequence, PE_ _ SP, exactly matched the consensus sequence of phosphorylation by MAPKs (33) . Moreover, the following sequence to S734 (_ _ SPVPP) is also found in BCL-2 (Fig. 1B) and the serine residue in the BCL-2 sequence is phosphorylated by JNK (42) . To determine if the S734 residue in the DRPLA protein is essential for phosphorylation with JNK, we constructed a mutant fragment, DR-i734A, in which S734 was substituted to alanine. In contrast to the normal counterpart, the mutant fragment was not phosphorylated in the recombinant activation system and the immune complex kinase assay for JNK ( Fig. 6A and B) .
To show immunological evidence for phosphorylation of S734, we produced two antibodies (epitopes of which are shown in Fig. 1B) and assessed their specific reactivity in ELISA assay (Fig. 6C) . The raised anti-phosphoserine 734 antibody (anti-DRs) reacted with the phosphorylated DR-i fragment in the recombinant JNK system, but not with nonphosphorylated counterparts in western blotting. The anti-DRPLA peptide antibody (anti-DRb) reacted with both (Fig. 6D) . These results were consistent with the recombinant JNK system described above, and the S734 residue was the main target by JNK.
Serine 734 is phosphorylated in the rat brain
The rat DRPLA protein has 93% homology to its human counterpart and is smaller by two amino acid residues (43) . Since the peptide sequences used for raising the antiphosphopeptide antibodies are exactly the same in both species (Fig. 1B) , we analyzed the phosphorylated state of the rat DRPLA protein by western blotting with the raised antibodies (Fig. 7) . The expression level of the DRPLA protein detected with the anti-DRb antibody was consistent with our previous results on the level of mRNA in northern blotting (4); where it was high in the brain and low in the pancreas and testis (Fig. 7A) . The major form in the brain (150 kDa protein) was also reactive with the anti-DRs antibody, which indicated that S734 in the DRPLA protein in the rat brain tissues was phosphorylated (Fig. 7B) . This form was also detected with the anti-DRa antibody (data not shown). When the brain samples were treated with alkaline phosphatase, the major form migrated faster and almost lost the immunoreactivity to the anti-DRs antibody (Fig. 7C) . These data were consistent with phosphorylation at S734. 
DISCUSSION
We report evidence for phosphorylation of the DRPLA protein, the product of the gene responsible for the polyglutamine disease, dentatorubral-pallidoluysian atrophy. The endogenous form was phosphorylated and the phosphorylation was mainly mediated by JNK.
JNK is activated in the critical process of embryonic morphogenesis, as well as in response to environmental stress such as radiation and high osmotic pressure (44) . The activation of JNK requires its phosphorylation mediated by MKK 4 and 7 (38, 39) . These two MKKs are activated by MKK kinases such as MEKK1. Activated JNK phosphorylates subsets of proteins including c-Jun, and up-regulates transcriptions of stress-responsive genes in various cells (45, 46) . In neurons, JNK3 is highly and consistently phosphorylated because of the synergistic activation of MKK4 and 7. Thus, DRPLA, one of the substrates of JNK3 as demonstrated in this report, may have a function in the brain coupled with activated JNK (47) (48) (49) .
We identified the S734 residue of the DRPLA protein as a phospho-acceptor site in the recombinant system as well as in the brain tissues. However, phosphorylation of this residue was not detectable with the endogenous form of DRPLA protein in cultured cells with the same technique (data not shown). This may be accounted for by a weaker activity of JNK in cultured cells, while consistent activation of JNK is known in the brain at a similar level of the recombinant JNK system (49) . The phosphorylation may be coupled to the activation of a protease. The molecular size of DRPLA protein detected in the rat brain with the specific phosphopeptide antibody was 150 kDa, which was slightly smaller than that expected from the sequence and the results with the human protein. The phosphorylated forms of HA-tagged human DRPLA gradually disappeared after osmotic treatment, as demonstrated in Fig. 5 . Although we did not directly detect degraded forms, caspase-3 may be one of the candidates involved. We previously reported the DRPLA protein is a substrate of caspase-3 and about 10 kDa from the N-terminus was cleaved off (24) .
Both the normal and abnormal forms of DRPLA protein were phosphorylated by the JNK recombinant system. However, precise kinetic analyses showed a reduced affinity of JNK for the abnormal protein. Furthermore, the abnormal protein expressed in cultured cells showed a subtle mobility shift in the JNK activation condition with osmotic pressure. It may be possible that a slight reduction of the affinity in the in vitro system causes considerable effects in a physiological condition, i.e. delay in a certain cascade reaction. Two other polyglutamine disease products, Huntingtin and androgen receptor, have recently been reported to be phosphorylated by an S/T kinase, Akt, which mediates the survival signal of IGF-I (50-52). As the DRPLA protein is already known to be situated in the insulin/IGF-I signaling cascade (25) , three polyglutamine diseases products seem to be connected by the signal transduction of IGF-I. As IGF-I is one of the main neurotrophic factors, neurodegeneration in polyglutamine diseases may be solved by a function of IGF-I. 
MATERIALS AND METHODS
Plasmid constructions
Original cDNA clones for DRPLA were previously described (2, 4) . The DNA fragment including the entire coding region of the DRPLA gene was subcloned into pBluescript SK(À) phagemid (Stratagene) for in vitro translation experiments, and a cpDNA-3xHA vector (kindly provided by Dr John C. Reed) for expression of HA-tagged proteins. cDNA fragments (shown in Fig. 1A ) amplified by PCR methods were subcloned into a pGEX-3X vector (Pharmacia) to generate GST fusion proteins. Plasmid harboring a point mutation was obtained by PCRmediated mutagenesis (53) .
Antibodies
Epitopes for the following three antibodies are indicated in Figure 1 . A rabbit polyclonal antibody which specifically reacted to a phosphorylated serine 734 residue in the DRPLA protein (anti-DRs) was raised against phosphopeptide ETPEpSPVPP (MBL Nagoya Japan). The serum was affinity-purified with the antigen peptide, and the reactivity to the non-phosphorylated peptide was eliminated with the affinity column. An anti-DRPLA peptide antibody (anti-DRb) was raised against phosphopeptide RSPpSPPPK, but it unexpectedly reacted to the non-phosphorylated counterpart as well as the antigen peptide. A rabbit polyclonal antibody raised against the recombinant human DRPLA protein (anti-DRa) was described previously (24) . The following antibodies are also used: polyclonal anti-JNK1 antibody C-17 (Santa Cruz), monoclonal anti-JNK antibody (Pharmingen), anti-activated JNK antibody (Promega), monoclonal anti-phosphoserine antibody PSR-45 (Sigma), anti-HA antibody (Roche), anti-b actin antibody (Santa Crutz) and anti-human acid b-galactosidase antibody (54) .
Preparation of recombinant proteins
Fragments of the DRPLA protein fused with GST were produced and purified as described previously (25) . Translation products of the full-length DRPLA genes were produced with the TNT coupled reticulocyte lysate mixture in vitro (Promega). The radio-labeled and non-labeled products were made in the presence and absence of [ 35 S]methionine, respectively. To quantify the translation products, the labeled mixture was resolved by SDS-PAGE, and the radioactivity of the DRPLA protein was measured as Photo-Stimulated Luminescence (PSL) with a Fuji BAS 2000 PhosphorImager (Fuji Film, Japan). One unit (U) was defined as an amount of the mixture which gave 1 PSL unit/min of 35 S. The non-labeled mixtures, equivalent to 1, 2 and 4 U of the labeled counterparts, were subjected to the in vitro phosphorylation study.
In vitro phosphorylation assay in a recombinant activation system for JNK In the recombinant system, JNK3 was synergistically activated by two forms of MKK, constitutive active MKK7 and native MKK4 that is activated by constitutive active MEKK1, as described previously (38) (39) (40) . The mixture contains 100 ng of four GST-fusion proteins, JNK3, MKK4, MKK7 and MEKK1, in kinase buffer (50 mM Tris-Cl pH 7.5, 10 mM MgCl 2 , 125 mM ATP, 1 mM DTT, 2 mM EDTA-Na and 500 mM NaVO 4 ). The fragments of the DRPLA protein fused with GST (100 ng equivalent) and the in vitro translation products of the DRPLA protein (1-4 U) were incubated in 10 ml of the mixture, with 5 mCi of [g- 32 P]ATP if needed, at 30 C for the indicated periods. Samples were resolved by SDS-PAGE and visualized with the PhosphorImager.
Cell culture
A human neuroblastoma cell line, SH-SY5Y, was maintained in RPMI1640 with 10% fetal bovine serum and transfected with plasmids using Lipofectamine PLUS (GIBCOBRL). For the activation of JNK with high osmotic pressure, cells were preincubated in the medium with 500 mM of Na 3 VO 4 for 15 min. Then D(À)-sorbitol was added at a final concentration of 1 M and the incubation was continued for the indicated periods. For inhibition of the JNK kinase activity, a reversible ATPcompetitive inhibitor, SP600125 (25 mM, BIOMOL), was added to the media 15 min prior to the sorbitol stimulation (41) .
Immune complex protein kinase assay SH-SY5Y cells were lysed in a lysis buffer (20 mM Tris-Cl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 1 mM Na 3 VO 4 , 1 mg/ml leupeptin and 1 mM PMSF). The lysates were sonicated and centrifuged. An aliquot of cleared lysates (100 mg of protein) was immunoprecipitated with the anti-JNK antibody C-17 for 2 h. The immune complex was used for a kinase assay with 5 mCi of [g-32 P]ATP and 2 mg of the GST-fusion protein in a kinase buffer (20 mM Hepes pH 7.4, 10 mM MgCl 2 and 200 mM Na 3 VO 4 ). After incubation at 30 C for 30 min, the samples were resolved by SDS-PAGE. Onetenth of the immune complex was analyzed by western blotting with an anti-monoclonal anti-JNK antibody.
Phosphatase treatment
SH-SY5Y cells and tissues from adult rats (male, Wistar rats) were homogenized in the Tris/MgCl 2 buffer (50 mM Tris-Cl pH 7.5 and 1 mM MgCl 2 ), sonicated for 30 s and centrifuged. Cleared lysates were incubated with calf intestine alkaline phosphatase (2 U for 10 mg protein, Sigma) at 30 C for 15 min, and the reaction was terminated with phosphatase inhibitors (Sigma).
Western blotting, immunoprecipitation and ELISA assay
The details of procedures for immunoprecipitation and western blotting were described previously (25) . Briefly, an aliquot containing 100 ng of GST-fusion proteins, and 30 mg of protein extracts was subjected to western blotting with 1 :500, 1: 500, 1 :200, 1 :200 and 1: 1000 diluted anti-GST, DRa, DRb, DRs and HA antibodies, respectively. To confirm equal loading of protein samples, the blotted membranes were re-probed with the 1 :400 and 1:250 diluted anti-b actin and anti-b galactosidase antibodies, respectively. The endogenous DRPLA protein was immunoprecipitated with the anti-DRa antibody from 500 mg protein of cell lysates and blotted with the 1:100 diluted anti-phosphoserine antibody. The ELISA assay using synthetic peptides as antigens and titration assays with anti-DRb and anti-DRs antibodies were performed according to the standard methods.
